当前位置:
X-MOL 学术
›
Diabetes Obes. Metab.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes.
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2020-03-01 , DOI: 10.1111/dom.14018 Skander Mulder 1 , Ann Hammarstedt 2 , Sunil B Nagaraj 1 , Viji Nair 3 , Wenjun Ju 3 , Jonatan Hedberg 2 , Peter J Greasley 2 , Jan W Eriksson 4 , Jan Oscarsson 2 , Hiddo J L Heerspink 1
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2020-03-01 , DOI: 10.1111/dom.14018 Skander Mulder 1 , Ann Hammarstedt 2 , Sunil B Nagaraj 1 , Viji Nair 3 , Wenjun Ju 3 , Jonatan Hedberg 2 , Peter J Greasley 2 , Jan W Eriksson 4 , Jan Oscarsson 2 , Hiddo J L Heerspink 1
Affiliation
To investigate which metabolic pathways are targeted by the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin to explore the molecular processes involved in its renal protective effects.
中文翻译:
基于代谢组学的分子通路分析钠-葡萄糖协同转运蛋白 2 抑制剂达格列净如何减缓糖尿病患者的肾功能衰退。
研究钠-葡萄糖协同转运蛋白 2 抑制剂达格列净靶向哪些代谢途径,以探索其肾脏保护作用所涉及的分子过程。
更新日期:2020-03-01
中文翻译:
基于代谢组学的分子通路分析钠-葡萄糖协同转运蛋白 2 抑制剂达格列净如何减缓糖尿病患者的肾功能衰退。
研究钠-葡萄糖协同转运蛋白 2 抑制剂达格列净靶向哪些代谢途径,以探索其肾脏保护作用所涉及的分子过程。